Detalles de la búsqueda
1.
An illness-death multistate model to implement delta adjustment and reference-based imputation with time-to-event endpoints.
Pharm Stat
; 23(2): 219-241, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37940608
2.
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model.
J Pharmacokinet Pharmacodyn
; 48(1): 39-53, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32930923
3.
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.
J Pharmacokinet Pharmacodyn
; 48(1): 21-38, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32929612
4.
Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol.
BMC Nephrol
; 21(1): 242, 2020 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32600374
5.
MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a "de jure" estimand.
Pharm Stat
; 19(6): 909-927, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32725810
6.
Quality-of-life-adjusted hazard of death: a formulation of the quality-adjusted life-years model of use in benefit-risk assessment.
Value Health
; 17(2): 275-9, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24636387
7.
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Eur J Drug Metab Pharmacokinet
; 39(1): 1-9, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23754514
8.
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Br J Clin Pharmacol
; 75(2): 440-9, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22642721
9.
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Biopharm Drug Dispos
; 34(8): 431-41, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23929659
10.
Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney Study.
J Nephrol
; 36(6): 1639-1649, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289366
11.
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Eur Heart J
; 32(20): 2541-54, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21878434
12.
Single portal arthroscopic temporomandibular joint discopexy: Technique and results.
J Craniomaxillofac Surg
; 49(3): 171-176, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33546966
13.
Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema.
Int J Retina Vitreous
; 5: 28, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31388454
14.
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
Lancet Diabetes Endocrinol
; 6(12): 925-933, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413396
15.
Transcultural adaptation and validation of the Spanish language version of the questionnaire OQLQ for the assessment of quality of life in orthognathic patients.
J Clin Exp Dent
; 10(12): e1184-e1191, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30697377
16.
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Adv Ther
; 34(11): 2466-2480, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29076107
17.
Is increasing urinary albumin a better marker for microvascular than for macrovascular complication of type 2 diabetes mellitus?
Nephron Clin Pract
; 101(3): c116-21, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16015000
18.
A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines.
Drug Saf
; 38(11): 1049-57, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26353915
19.
¿Cuál es su diagnóstico? / What is your diagnosis?
Rev. esp. cir. oral maxilofac
; 41(3): 153-155, jul.-sept. 2019. ilus
Artículo
en Español
| IBECS (España) | ID: ibc-191780
20.
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Clin Pharmacol Drug Dev
; 3(3): 194-201, 2014 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27128609